Engelhardt M, MacKenzie K, Drullinsky P, Silver RT, Moore MAS. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Research 2000; 60: 610-617.
Han W, Ye Q, Moore MAS. A soluble form of human Delta-Like-1 inhibits differentiation of hematopoietic progenitor cells. Blood 2000; 95: 1616-1625.
Jo D-Y, Rafii S, Hamada T, Moore MAS. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest 2000; 105: 101-111.
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MAS, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34 cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-958
Lane WJ, Dias S, Hattori K, Heissig B, Choy M, Rabbany SY, Wood J, Moore MAS, Rafii S. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 2000; 96: 4152-4159.
Kikuchi T, Miyazawa N, Moore MAS, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naïve dendritic cells. Cancer Res 2000; 60: 6391-6395.
Kikuchi T, Worgall S, Singh R, Moore MAS, Crystal RG. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4-T cells. Nature Medicine 2000; 6: 1154-1159.
Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, MAS Moore, Rafii S. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
MacKenzie KL, Franco S, May C, Sadelain M, Moore MAS. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Research 2000; 259: 336-350.
Fushimi T, Kojima A, Moore MAS, Crystal RG. Macrophage inflammatory protein 3a attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000; 105: 1383-1393.
Mackenzie KL, Hackett NR, Crystal RG, Moore MAS. Adenoviral vector-mediated gene transfer to primitive human hematopoietic progenitor cells: Transduction and quantification in long-term culture. Blood 2000; 96: 100-108.
Kikuchi T, Moore MAS, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against pre-existing murine tumors. Blood 2000; 96: 91-99.
Flasshove M, Leonard JP, Bardenheuer W, Moore MAS. Increased resistance and selection in paclitaxel for peripheral blood progenitor cells following transduction with the MDR1 gene. Tumor Diagnostik & Therapie 2000; 21: 51-58.
Moore MAS. Commentary: Umbilical cord blood: An expendable resource. J Clin Invest 2000; 105: 855-856.
Lane WJ, Hattori K, Dias S, Peerschke EI, Moore MA, Blanset DL, Lang PC, Petrone M, Rafii S. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp Hematol 2001; 29: 1417-1424.
Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MAS, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine 2001; 7: 1194-1201.
Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857-10862.
Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193: 1005-1014.
Moore MAS, Hattori K, Heissig B, Shieh J-H, Dias S, Crystal RG, Rafii S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF and Angiopoietin. Annals NY Acad Sci 2001; 938: 36-45.
Moore MAS. The role of chemoattraction in cancer metastases. BioEssays 2001; 23: 674-676.
Franco S, MacKenzie KL, Dias S, Alvarez S, Rafii S, Moore MAS. Clonal variation in phenotype and lifespan of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT). Exp Cell Res 2001; 268: 14-25.
Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh J-H, Hackett N, Quitoriano MS, Crystal RG, Rafii S, Moore MAS. Plasma elevation of stromal derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-3360.
Feugier P, Jo D-Y, Shieh J-H, MacKenzie KL, Rafii S, Crystal RG, and Moore, MAS. Ex vivo Expansion of Stem and Progenitor Cells in Co-Culture of Mobilized Peripheral Blood CD34 Cells on Human Endothelium Transfected with Adenovectors Expressing Thrombopoietin, C-kit Ligand and Flk-2 Ligand. J of Hematotherapy & Stem Cell Research 2002; 11: 127-138.
Mulloy JC, Cammenga J, MacKenzie KL, Moore MAS, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99: 15-23.
Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA, Werb Z, Lyden D, Rafii S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1( +) stem cells from bone-marrow microenvironment. Nature Medicine 2002; 8: 841-849.
MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, Moore MAS. Multiple stages of malignant transformation of human endothelial cells modeled by co-expression of telomerase reverse transcriptase, SV40 large T antigen and oncogenic N-ras. Oncogene 2002; 21: 4200-4211.
Takebe N, Li-Cheng X, MacKenzie KL, Bertino JR, Moore MAS.. Methotrexate selection of long term culture initiating cells following transduction of CD34 cells with a retrovirus containing a mutated human of dihydrofolate reductase gene. Cancer Gene Therapy 2002; 9: 308-320.
Boklan J, Nanjangud G, MacKenzie KL, May C, Sadelain M, and Moore MAS. Limited Proliferation and Telomere Dysfunction Following Telomerase Inhibition in Immortal Murine Fibroblasts. Cancer Research 2002; 62: 2104-2114.
Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett N, Crystal RG, Besmer P, Lyden D, Moore MAS, Werb Z, Rafii S. Recruitment of stem cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
Moore MAS. Putting the neo into neoangiogenesis. J Clin Invest 2002; 109: 313-315.
Moore MAS. Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing. J Cell Biochem Suppl. 2002; 38: 29-38.
Franco S, Ozkaynak MF, Sandoval C, Tugal O, Jayabose S, Engelhardt M, Moore MAS. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 2003. 17:401-410.
Moldenhauer A, Nociari MM, Dias S, Lalezari P, Moore MAS. Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes. Vox Sanguinis 2003, 84:228-236.
Moore MAS. In vitro and in vivo hematopoiesis. In: Zucker-Franklin, Greaves MF, Grossi CE, Marmont Am, eds: Atlas of Blood Cells: Function and Pathology. 3rd edition. Arti Grafiche Salea, Milan. 2003, pp1-38.
Wu K, Orme L, Shaughnessy J, Jacobson JJ, Barlogie B, Moore MAS. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood. 2003 101:4982-4989.
Wang E, O'Connor O, She Y, Zelenetz A, Sirotnak FM, Moore MAS. Activity of a novel anti-folate (PDX, 10-propargyl-10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leukemia & Lymphoma 2003, 44:1027-1035.
Rafii S, Avecilla S, Shmelkov S, Shido K, Tejada R. Moore MA, Heissig B, Hattori K. Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Ann NY Acad Sci 2003 996:49-60.
Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jahnwar S, Moore MAS, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic stem cells using a single genetic element. Blood. 2003, 102:4369-76.
Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K, Perrier AL, Bruses J, Rubio ME, Topf N, Tabar V, Harrison NL, Beal MF, Moore MA, Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol. 2003, 21:1200-7.
Wang ES, Wu K, Chin AC, Pongracz K, Gryaznov S, Moore MAS. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004;103:258-66.
Ghannam G, Takeda A, Camarata T, Moore MA, Viale A, Yaseen NR. The oncogene Nup98-HOXA9 induces gene transcription in myeloid cells. J Biol Chem. 2004, 279:866-75.
Zhang Y, Morrone G, Zhang J, Chen X, Lu X, Ma L, Moore M, Zhou P. CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein. EMBO J. 2003, 22:6057-6067.
Bond HM, Mesuraca M, Carbone E, Bonelli P, Agosti V, Amodio N, De Rosa G, Di Nicola M, Gianni MA, Moore MAS, Hata A, Grieco M, Morrone G, Venuta S. Early hematopoietic zinc finger protein (EHZF), the human homologue for Evi3 is highly expressed in primitive human hematopoietic cells. Blood 2003. 103:2062-70.
Moldenhauer A, Nociari M, Lam G, Salama A, Rafii S, Moore MAS. Tumor necrosis factor alpha-stimulated endothelium: an inducer of dendritic cell development from hematopoietic progenitors and myeloid leukemic cells. Stem Cells 2004 22:144-157.
Perez LE, Alpdogan O, Shieh J-H, Wong D, Merzouk A, Salari H, O'Reilly RJ, Crystal R, van den Brink M, Moore MAS. Increased plasma levels of stromal derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony forming cells (CFC) in NOD/SCID mice. Exp Hematology 2004. 32:300-307.
Agosti V, Corbacioglu S, Ehlers I, Waskow C, Sommer G, Berrozpe G, Kissel H, Tucker CM, Manova K, Moore MA, Rodewald H-R, Besmer P. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med. 2004, 199:876-78.
Moore, MAS. COMMENTARY: The role of cell migration in the ontogeny of the lymphoid system. Stem Cells Dev. 2004, 13:1-21.
Moore MAS. The “Stem Cell Leukemia” Gene: What's in a Name? Blood 2004. 103: 3249-50.
Lanza RP, Moore MAS, Wakayama T, Perry ACF, Shieh J-H, Hendrikx J, Leri A, Chimenti S, Monsen A, Nurzynska D, West MD, Kajstura J, Anversa P. Regeneration of the infarcted heart with stem cells derived by nuclear transplantation. Circulation Research, 2004;94:820-7.
Gammaitoni L, Weisel KC, Gunetti M, Wu KD, Bruno S, Pinelli S, Bonati A, Aglietta M, Moore MAS, Piacibello W. Elevated telomerase activity, minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood 2004, 103:4440-8.
Ye Q, Shieh J-H, Morrone G, Moore MAS. Expression of constitutively active Notch4 (Int-3) modulates myeloid proliferation and differentiation and promotes expansion of hematopoietic progenitors. Leukemia, 2004, 18:777-87.
Nimer SD, Moore MAS. Effects of the leukemia-associated AML1/ETO protein on hematopoietic stem and progenitor cells. Oncogene. 2004, 23:4249-54.
Moldenhauer A, Shieh J-H, Pruss A, Salama A, Moore MAS. Tumor necrosis factor alpha enhances the adenoviral transduction of CD34(+) hematopoietic progenitor cells. Stem Cells. 2004, 22:283-291.
Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg D, Salama A, Seeger K, Moore MA, Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol. 2004, 76:623-633.
Schuringa JJ, Chung KY, Morrone G, Moore MAS. Constitutive activation of STAT5 promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med. 2004, 2000:623-635.
Wang E, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MAS. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenographs in vivo. Blood. 2004, 104: 2893-2902.
Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore MA, Bertino JR. Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Mol Ther. 2004 Sep;10(3):574-84.
Chung KY, Morrone G, Schuringa JJ, Wong B, Dorn DC, Moore MA. Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood. 2005, 105:77-84.
Gaul C, Njardarson JT, Shan D, Dorn DC, Wu KD, Tong WP, Huang XY, Moore MA, Danishefsky SJ. The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis. J Am Chem Soc. 2004,126:11326-37.
Moore Chapter 18 The Ontogeny of the Hematopoietic System in: Handbook of Adult and Fetal Stem Cells. Eds Lanza RP, Blau HM, Melton DA, Moore MAS, Thomas ED, Verfaillie CM, Weissman IL, West MD. Handbook of Stem Cells, Adult and Fetal, Vol 2. Elsevier Academic Press, Inc, U.S.A. 2004, pp 159-174.
Moore, MAS. Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol 2005, 33:719-737.
Schuringa JJ, Wu K, Morrone G, Moore MA. Enforced activation of STAT5A facilitates the generation of embryonic stem-derived hematopoietic stem cells that contribute to hematopoiesis in vivo. Stem Cells. 2004, 22:1191-1204.
Weisel KC, Moore MA. Genetic and functional characterization of isolated stromal cell lines from the aorta-gonado-mesonephros region. Ann N Y Acad Sci. 2005 Jun;1044:51-9.
Cho YS, Wu K-D, Moore MAS, Chou T-C, Danishefsky SJ. Second-generation epothilones: discovery of fludelone and its extraordinary antitumor properties. Drugs of the Future 2005, 30:1-9.
Lanza R, Shieh J-H, Wettstein PJ, Sweeney RW, Wu K, Weisz A, Borson N, Henderson B, West MD, Moore MAS. Long-Term Bovine Hematopoietic Engraftment with Clone-Derived Stem Cells. Cloning and Stem Cells 2005;7:95-106.
Wu K-D, Cho YS, Katz J, Ponomarev V, Chen-Kiang S, Danishefsky SJ, Moore MAS. Investigation of anti-tumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A. 2005, 102; 10640-10645.
Wu KD, Moore MA. Determination of telomerase activity and telomere length. Methods Mol Med. 2005;113:207-23.
Moore MAS, The Ontogeny of the Hematopoietic System, in: Lanza R, Gearhart J, Hogan B, Melton D, Thomas ED, Thompson J, West M, eds. Essentials of Stem Cell Biology. Elsevier Inc, U.S.A. 2006, pp 177-186.
Feugier P, Li N, Jo DY, Shieh JH, MacKenzie KL, Lesesve JF, Latger-Cannard V, Bensoussan D, Crystal RG, Rafii S, Stoltz JF, Moore MA. Osteopetrotic mouse stroma with thrombopoietin, c-kit ligand, and flk-2 ligand supports long-term mobilized CD34+ hematopoiesis in vitro. Stem Cells Dev. 2005. 14:505-16.
Wierenga AT, Schepers H, Moore MA, Vellenga V, Schuringa JJ. STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBP{alpha}. Blood. 2006. 107:4326-33.
Moldenhauer A, Moore MAS, Schmidt K, Kiesewetter H, Salama A. Differences in the transmigration of different dendritic cells. Experimental Hematology. 2006. 34:745-752.
He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MAS, Massague J. Hematopoiesis controlled by distinct TIF1? and Smad4 branches of the TGF pathway. Cell. 2006;125:929-41.
Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MAS, Chen-Kiang S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of Cyclin-dependent kinase 4/6. Cancer Research. 2006. 66:7661-7667.
Weisel KC, Gao Y, Shieh J-H, Moore MAS. Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis. Exp Hematol. 2006. 34:1505-1516.
Moore MAS, Lee G. Chapter 13, Hematopoietic Cells. In Abelson JN, Simon MI eds. Methods in Enzymology. Vol 418 Embryonic Stem Cells. Elsevier Academic Press, Inc, U.S.A. 2006, pp 208-242.
Chung KY, Morrone G, Schuringa JJ, Shieh J-H, Zhang Y, Zhou P, and Moore MA. Enforced expression of NUP98-HOXA9 in human CD34+ cells provides a proliferative advantage and enhances stem cell self-renewal. Cancer Research 2006. 66:11781-11791.
Wen VW, Wu K, Baksh S, Hinshelwood RA, Lock RB, Clarke SJ, Moore MAS, MacKenzie KL. Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53-competent immortal endothelial cells. Cancer Research 2006, 66:10691-10700.
Wu K-D, Zhou L, Burtrum D, Ludwig DL, Moore MAS. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother. 2007;(56)3:343-357.
Angeles AR, Dorn DC, Kou CA, Moore MAS, Danishefsky SJ. Total synthesis of peribysin E necessitates revision of the assignment of its absolute configuration. Angewandte Chemie Int Ed 2007, 46: 1451-4.
Moore MAS, Dorn DC, Schuringa JJ, Chung KY, Morrone G. Constitutive activation of Flt3 and STAT5A enhance self-renewal and alter differentiation in normal and hematopoietic stem cells. Exp Hematol 2007, 35(suppl 1):105-116.
Lu S-J, Feng Q, Caballero S, Chen Y, Moore MAS, Grant MB, Lanza R. Generation of functional hemangioblasts from human embryonic stem cells. Nature Methods. Nature Methods. 2007. 4:501-9.
Moore MA, Chung KY, Plasilova M, Schuringa JJ, Shieh J-H, Zhou P and Morrone G. NUP98 dysregulation in myeloid leukemogenesis. Annals New York Acad Sci. 2007. 1106:114-142.
Moore MA. NUP98-HOXA9 Fusion. Encyclopedia of Cancer . 2nd Edition. Edt: Schwab M. Spinger-Verlag. In press.
Moore MAS. Hematopoietic Stem cells. Chapter 49 in Principles of Tissue Engineering. 3rd Edition. Eds Lanza, Langer and Vacanti. Elsevier Academic Press Inc. USA. 2007 pp735-748.
Kim K, Ng K, Rugg-Gunn PJ, Shieh JH, Jaenisch R, Wakayama T, Moore MA, Pedersen RA, and Daley GQ. Recombination signatures distinguish embryonic stem cells derived by parthenogenesis and somatic cell nuclear transfer. Cell Stem Cell 2007;1:346-352.
Bond HM, Mescura M, Amodio N, Mega T, Agosti T, Fanello D, Pelaggi D, Bullinger L, Grieco M, Moore MAS, Venuta S, Morrone G. Molecules in Focus: Early hematopoietic zinc finger protein-zinc finger protein 521: A candidate regulator of diverse immature cells. Int J Biochem & Cell Biol. 2007. (E-pub ahead of press.)
Weisel KC, Gao Y, Shieh J-H, Moore MAS. Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis. Exp Hematol. 2006. 34:1505-16.
Lee GS, Kim BS, Sheih JH, Moore M. Forced Expression of HoxB4 Enhances Hematopoietic Differentiation by Human Embryonic Stem Cells. Mol Cells. 2008;25:487-493.
Weisel K, Moore MAS, Kanz L, Moehle R. Extended In-vitro Expansion of Adult, Mobilized CD34+ Cells without Significant Cell Senescence using a Stromal Cell Co-culture System with Single Cytokine Support. Stem Cells Dev. 2009;18(2):229-34.
Dorn DC, Kou CA, Png KJ, Moore MA. The effect of cantharidins on leukemic stem cells. Int J Cancer. 2009 May 1;124(9):2186-99.
Moore MA. NUP98-HOXA9 Fusion. In “Encyclopedia of Cancer”. 2nd Edition. Edt Schwab M. Spinger-Verlag. 2009
Moore MA. Hematopoietic Stem Cells. Chapter 30. In “Regulatory Networks in Stem Cells”. Eds. Rajasekhar and Vemuri. Humana Press Inc. USA. 2009.
Moore MAS, Shieh JH, Lee G. Chapter 13, Hematopoietic Cells. In Abelson JN, Simon MI eds. Best of Series: Essential Stem Cell Methods. Elsevier Academic Press, Inc, U.S.A. 2009
Weisel K, Barberi T, Studer L, Kopp HG, Moore MA Wnt-1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells. Stem Cells Dev. 2009. May 7. [Epub ahead of print].
Deshpande S, Agosti V, Manova K, Moore MAS, Hardy MP, Besmer P. Kit ligand cytoplasmic domain is essential for basolateral sorting in vivo and has roles in spermatogenesis and hematopoiesis. Dev Biol. 2009 Oct 27. [Epub ahead of print].
Zheng Z, Oancea C, Steinert G, Beissert T, Henschler R, Moore MAS, Ruthardt M. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment in comparison to BCR/ABL. PLoS One. 2009 Oct 30;4(10):e7661.
Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M, Nimer SD. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells. 2009 Dec 4. [Epub ahead of print].
Oskarsson T, Nagorny P, Krauss I, Perez L, Mandal M, Yang G, Ouerfelli O, Xiao D, Moore MA, Massagué J, Danishefsky SJ. Diverted Total Synthesis Leads to the Generation of Promising Cell-Migration Inhibitors for Treatment of Tumor Metastasis: In vivo and Mechanistic studies on the Migrastatin Core Ether Analog. J Am Chem Soc. (PMC Journal - in process)
Weisel K, Kopp HG, Moore MA, Studer L, Barberi T. Wnt1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells. Stem Cells Dev. 2010 May;19(5):745-51.
Deshpande S, Agosti V, Manova K, Moore MAS, Hardy MP, Besmer P. Kit ligand cytoplasmic domain is essential for basolateral sorting in vivo and has roles in spermatogenesis and hematopoiesis. Dev Biol. 2010 Jan 15;337(2):199-210. Epub 2009 Oct 27.
Zheng Z, Oancea C, Steinert G, Beissert T, Henschler R, Moore MAS, Ruthardt M. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment in comparison to BCR/ABL. PLoS One. 2009 Oct 30;4(10):e7661.
Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M, Nimer SD. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells. 2010 Feb;28(2):308-17.
Morozov A, Downey RJ, Healey J, Moreira AL, Lou E, Franceschino A, Dogan Y, Leung R, Edgar M, LaQuaglia M, Maki RG, Moore MA. Benign mesenchymal stromal cells in human sarcomas. Clin Cancer Res. 2010 Dec 1;16(23):5630-40.
Eldjerou LK, Chaudhury S, de Baisre-de-Leon A, He M, Arcila ME, Heller G, O’Reilly RJ, Barker JN, Moore MAS. An In Vivo Model of Double Unit Cord Blood Transplantation that Correlates with Clinical Engraftment. Blood. 2010 Nov 11;116(19):3999-4006. Epub 2010 Jun 29.
Oskarsson T, Nagorny P, Krauss I, Perez L, Mandal M, Yang G, Ouerfelli O, Xiao D, Moore MA, Massagué J, Danishefsky SJ. Diverted Total Synthesis Leads to the Generation of Promising Cell-Migration Inhibitors for Treatment of Tumor Metastasis: In vivo and Mechanistic studies on the Migrastatin Core Ether Analog. J Am Chem Soc. 2010 Mar 10;132(9):3224-8.
Moore MA. A cancer fate in the hands of a samurai. Nat Med. 2010 Sep;16 (9):963-5.
Funasaka T, Nakano H, Wu Y, Hashizume C, Gu L, Nakamura T, Zhou P, Moore MA, Sato H, Wong RW. RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis. Cell Cycle. 2011. 10(9):1456-67.
Mega T, Lupia M, Amodio N, Horton SJ, Mesuraca M, Pelaggi D, Agosti V, Grieco M, Chiarella E, Spina R, Moore MAS, Schuringa JJ, Bond HM, Morrone G. Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors. Cell Cycle. 2011 Jul 1;10(13):2129-39.
Lecomte N, Njardarson J, Nagorny P, Yang G, Downey R, Ouerfelli O, Moore M, Danishefsky S. Emergence of Potent Inhibitors of Metastasis in Lung Cancer via Syntheses Based on Migrastatin. Proc Natl Acad Sci U S A. 2011 Sep 13; 108(37):15074-8. Epub 2011 Aug 1.
Amrani YM, Gill J, Matevossian A, Alonso ES, Yang C, Shieh JH, Moore MA, Park CY, Sant’Angelo DB, Denzin LK. The Paf Oncogene is Essential for Hematopoietic Stem Cell Function and Development. J. Exp Med Published August 15, 2011.
Shaykhiev R, Wang R, Zwick RK, Hackett NR, Leung R, Moore MAS, Downey RJ, Strulovici-Barel Y, Salit J, Crystal RG. Airway Basal Cells of Healthy Smokers Exhibit a Lung Cancer-associated Embryonic Stem Cell-like Program. Cancer Res (J Exp Med in press 2012).
analog (A-nuh-log)
In chemistry, a substance that is similar, but not identical, to another.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
antitumor (AN-tee-TOO-mer)
Having to do with stopping abnormal cell growth.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
blood (blud)
A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
cancer (KAN-ser)
A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of cancer. Carcinoma is a cancer that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are cancers that begin in the cells of the immune system. Central nervous system cancers are cancers that begin in the tissues of the brain and spinal cord. Also called malignancy.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
cell (sel)
The individual unit that makes up the tissues of the body. All living things are made up of one or more cells.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
embryonic (EM-bree-AH-nik)
Having to do with an embryo, which is an early stage in the development of a plant or animal.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
fetal (FEE-tul)
Having to do with a fetus. A fetus is an unborn baby that develops and grows inside the uterus. In humans, the fetal period begins 8 weeks after fertilization of an egg by a sperm and ends at birth.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
gene (jeen)
The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and most genes contain the information for making a specific protein.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
hematopoiesis (hee-MA-toh-poy-EE-sus)
The formation of new blood cells.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
IL
One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. ILs regulate immune responses. ILs made in the laboratory are used as biological response modifiers to boost the immune system in cancer therapy. An interleukin is a type of cytokine. Also called interleukin.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
in vitro (in VEE-troh)
In the laboratory (outside the body). The opposite of in vivo (in the body).
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
in vivo (in VEE-voh)
In the body. The opposite of in vitro (outside the body or in the laboratory).
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
L
A measure of volume for a liquid, using the metric system. One L is equal to 1,000 cubic centimeters (cc), 1,000 milliliters (mm), or 1.0567 quarts (qt). Also called liter.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
lung (lung)
One of a pair of organs in the chest that supplies the body with oxygen, and removes carbon dioxide from the body.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
M
In chemistry, M is the amount of a substance that has 6.023 x 10(23) atoms or molecules of that substance. Also called mole (chemical).
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
medicine (MEH-dih-sin)
Refers to the practices and procedures used for the prevention, treatment, or relief of symptoms of a diseases or abnormal conditions. This term may also refer to a legal drug used for the same purpose.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
National Institutes of Health (NA-shuh-nul IN-stih-TOOTS … helth)
A federal agency in the U.S. that conducts biomedical research in its own laboratories; supports the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helps in the training of research investigators; and fosters communication of medical information. Access the National Institutes of Health Web site at . Also called NIH.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
paclitaxel (PA-klih-TAK-sil)
A drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
resistance
Failure of a cancer to shrink after treatment.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
somatic (soh-MA-tik)
Having to do with the body.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
stem cell (stem sel)
A cell from which other types of cells develop. For example, blood cells develop from blood-forming stem cells.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
tissue (TIH-shoo)
A group or layer of cells that work together to perform a specific function.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
tumor (TOO-mer)
An abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Tumors may be benign (not cancer), or malignant (cancer). Also called neoplasm.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)